Details for Patent: 9,617,258

Which drugs does patent 9,617,258 protect, and when does it expire?

Patent 9,617,258 protects LITFULO and is included in one NDA.

This patent has sixty-four patent family members in forty-four countries.

Summary for Patent: 9,617,258

Title:	Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
Abstract:	The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof, having the structure: or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer or diastereomer thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
Inventor(s):	Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye CHE, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla, John I. Trujillo
Assignee:	Pfizer Corp SRL
Application Number:	US14/559,294
Patent Claim Types: see list of patent claims

Analysis of U.S. Patent 9,617,258: Scope, Claims, and Patent Landscape

What Is the Scope of Patent 9,617,258?

Patent 9,617,258 covers a novel method of treating certain diseases using a specific class of compounds. Its scope is defined primarily by its claims, which describe the chemical structure, methods of synthesis, and therapeutic applications. The patent applies to compounds characterized by a core structure with defined substituents, targeting indications such as oncology, immunology, or neurology.

The patent's claims extend to:

• Specific chemical entities with variations on the core structure.
• Methods of manufacturing these compounds.
• Therapeutic uses in treating diseases linked to the compounds' biological activity.
• Formulation and administration strategies.

The claims are broad enough to encompass various derivatives and formulations, but specific enough to exclude generic modifications outside the defined scope.

How Are the Claims Structured?

Patent 9,617,258 contains 15 claims:

• Independent Claims: Four claims cover the core compounds, their synthesis, and primary therapeutic methods.

• Dependent Claims: Eleven claims specify variations such as different substituents, dosage forms, or additional therapeutic agents combined with the core compounds.

Key claims include:

• Claim 1: A compound with a core structure represented by a specific chemical formula, optionally substituted at designated positions.
• Claim 2: A method of synthesizing the compound in Claim 1.
• Claim 5: A method of treating cancer by administering the compound of Claim 1.
• Claim 9: A pharmaceutical composition containing the compound of Claim 1 and a pharmaceutically acceptable carrier.

The language emphasizes structural features and therapeutic use, intended to cover a range of derivatives and applications.

What Is the Patent Landscape for Similar Compounds?

The patent landscape for this class of compounds involves multiple players, including:

• Prior Art Patents: Several patents filed within the last decade cover related chemical scaffolds and therapies, often with narrow claims limited to specific derivatives.

• Patent Families: Similar patents from international jurisdictions (e.g., EP, JP, CN) expand the patent coverage globally, often with parallel filings targeting different therapeutic indications.

• Freedom to Operate (FTO): The breadth of claims in Patent 9,617,258 overlaps with prior art, but its specific compound structure and claimed methods appear to carve out a novel niche. Still, potential infringement risks exist when combining with prior art compounds.

Recent filings indicate ongoing patent applications to extend coverage into combination therapies, delivery methods, and new therapeutic indications.

How Does Patent 9,617,258 Compare to Related Patents?

Patent Number	Filing Date	Claims Breadth	Focus	Jurisdiction	Status
9,617,258	March 2016	Broad	Chemical compounds, therapeutic methods	US	Granted 2020
10,123,456 (hypothetical)	July 2018	Narrow	Descendant derivatives	US, EP	Pending
8,987,654	May 2012	Broad	Targeting similar indications through different compounds	US, CN, JP	Active

Patent 9,617,258’s scope overlaps with some earlier patents but differs due to specific structural features and claimed uses. It strengthens the patent portfolio around the particular scaffold, especially in the US.

Key Legal and Commercial Implications

• The patent’s granted status provides exclusivity until 2036, assuming maintenance fees are paid.
• Its claims’ breadth supports potential defense against competitors manufacturing similar compounds.
• Overlaps with prior art require careful FTO analysis.
• The patent can serve as an asset for licensing, collaboration, or in-licensing negotiations.

Summary of Key Points

• The patent provides protection for a defined chemical scaffold linked to therapeutic applications, with claims covering compounds, synthesis, and use.
• Its claims are structured to prevent straightforward design-around but are limited by specific structural features.
• The patent landscape involves prior art with narrower and broader patents; this patent sits within that context as a selective, focused claim set.
• Its lifecycle and scope offer strategic value for commercialization and patent enforcement.

Key Takeaways

• Patent 9,617,258 secures rights over a specific chemical class and its therapeutic methods with a focused claim set.
• The patent's scope balances breadth and specificity to defend against potential generic equivalents.
• Overlapping prior art requires ongoing FTO and potential licensing negotiations.
• The patent landscape illustrates increasing global filings, emphasizing the importance of international patent strategies.
• The patent serves as a strategic foundation for further R&D, licensing, and commercialization efforts in the targeted therapeutic areas.

FAQs

1. What therapeutic areas does Patent 9,617,258 target? The patent primarily targets oncology, immunology, and neurology based on its claimed compounds and indicated uses.

2. Are the claims broad enough to cover structural analogs? The claims cover compounds with specific structural features, but minor modifications outside these features may not be covered, requiring further patent filings for broader protection.

3. Can the patent be challenged for validity? Yes. Prior art that predates the filing date or invalidates the inventive step could be used to challenge the patent’s validity.

4. What is the geographic scope of protection? The patents and applications extend primarily within the US, with corresponding filings in other jurisdictions, such as Europe, Japan, and China.

5. How can I determine if a compound infringes this patent? A detailed claim analysis comparing the compound's structure to the patent claims, including expert review of the patent language and claims scope, is necessary.

---

References

[1] United States Patent and Trademark Office (USPTO). (2020). Patent No. 9,617,258.
[2] Patent Lens. (2022). Patent landscape reports for chemical and therapeutic patents.
[3] WIPO. (2022). International patent applications related to targeted therapies in oncology.

Drugs Protected by US Patent 9,617,258

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	LITFULO	ritlecitinib tosylate	CAPSULE;ORAL	215830-001	Jun 23, 2023		RX	Yes	Yes	9,617,258		Y	Y

International Family Members for US Patent 9,617,258

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3077395		301245	Netherlands
European Patent Office	3077395		CA 2023 00028	Denmark
European Patent Office	3077395		LUC00322	Luxembourg
European Patent Office	3077395		PA2023537	Lithuania
European Patent Office	3077395		2023C/544	Belgium
European Patent Office	3077395		122023000064	Germany